Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Resonance SpecialtiesBOM:524218 +3.94%70 Days Payable is 124.96 as of Mar. 2026, which is 19% above its 10-year median of 105.02. GuruFocus rates BOM:524218 with a GF Score™ of 70/100 and a GF Value™ of ₹140.91 (Fairly Valued). The stock has 7 warning signs investors should review. Among 1,554 Chemicals companies, Resonance Specialties ranks better than 67.05% on this metric.
Resonance Specialties Days Payable Historical Data
* Premium members only.
The historical data trend for Resonance Specialties's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Chemicals subindustry, Resonance Specialties's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Resonance Specialties Days Payable vs Chemicals Industry
For the Chemicals industry and Basic Materials sector, Resonance Specialties's Days Payable distribution charts can be found below:
* The bar in red indicates where Resonance Specialties's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Resonance Specialties's Days Payable for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Resonance Specialties (BOM:524218) has a Days Payable of 124.96 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Resonance Specialties and its competitors. This is 19% above median its historical median of 105.02. Over the past decade, Resonance Specialties' Days Payable has ranged from 69.48 to 193.87. According to the industry distribution chart, Resonance Specialties ranks #512 out of 1554 companies in the Chemicals industry, placing it in the top 32.9%.
Is Resonance Specialties' Days Payable too high?
Resonance Specialties' current Days Payable of 124.96 is 19% above median its 10-year median of 105.02. Over the past 10 years, this metric has ranged from a low of 69.48 to a high of 193.87. The Chemicals industry median Days Payable is 59.57. Resonance Specialties' value of 124.96 is 109.8% above this industry median. Based on the distribution chart, Resonance Specialties ranks #512 out of 1554 companies in the Chemicals industry, which is above the industry midpoint. Overall, Resonance Specialties has a GF Score™ of 70/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Resonance Specialties' Days Payable compare to DOW?
According to the Chemicals industry distribution chart, Resonance Specialties ranks #512 out of 1554 companies for Days Payable. This puts Resonance Specialties in the upper half of its industry. The industry median Days Payable is 59.57. Resonance Specialties' value of 124.96 is 109.8% above this benchmark. Historically, Resonance Specialties' own Days Payable has ranged from 69.48 to 193.87 over the past decade. While the company's 10-year median is 105.02 vs. the industry median of 59.57, Resonance Specialties has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Chemicals company?
The median Days Payable among Chemicals companies is 59.57, based on 1,554 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Resonance Specialties's current Days Payable of 124.96 is 109.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Resonance Specialties and its competitors. For the Chemicals industry, the median Days Payable is 59.57 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Resonance Specialties's current Days Payable is 124.96, which is 19% above median its own 10-year median of 105.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Resonance Specialties stock overvalued right now?
Based on GuruFocus' analysis, Resonance Specialties (BOM:524218) is currently considered Fairly Valued. The stock's GF Value™ is ₹140.91, compared to a current price of ₹149.15 — trading 5.8% above its estimated fair value. The current Days Payable is 124.96, which is 19% above median its 10-year median of 105.02 and 109.8% above the Chemicals industry median of 59.57. Resonance Specialties' overall GF Score™ is 70/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Resonance Specialties (BOM:524218), the current Days Payable is 124.96 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Resonance Specialties (BOM:524218) Overvalued in 2026?
Based on GuruFocus' analysis, Resonance Specialties stock appears to be overvalued.
The current stock price of ₹149.15 is trading 5.8% above its estimated GF Value™ of ₹140.91.
GuruFocus considers Resonance Specialties to be Fairly Valued.
Key valuation signals for BOM:524218:
Days Payable: 124.96 (19% above median its 10-year median of 105.02)
GF Value™: ₹140.91 vs. price of ₹149.15 (5.8% above fair value)
Industry Position: 109.8% above the Chemicals median (#512 of 1554)
No single metric tells the full story. See the BOM:524218 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Resonance Specialties Ltd is engaged in the manufacturing of chemicals. The company is manufacturing Pyridine, Picoline, Cynopyridine, and derivatives of the same. Bulk drugs and nutritional products are tolls converted. It delivers pyridine and related products. The company has only one segment which is Chemical Manufacturing. The company also manufactures anti-tuberculosis products such as Isoniazid. Geographically. It operates in India and Outside India. The majority of segment revenue is from Outside India.
70GF Score
Get the complete analysis for BOM:524218
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:524218 has been successfully added to your 
